News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Apr 23, 2021 10:01am EDT

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

Apr 16, 2021 10:00am EDT

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX

Apr 15, 2021 8:00am EDT

Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology

Mar 09, 2021 4:01pm EST

Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 05, 2021 8:00am EST

Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market

Feb 25, 2021 4:05pm EST

Brickell Biotech to Participate in March Virtual Investor Conferences

Feb 23, 2021 4:01pm EST

Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021

Jan 19, 2021 7:00am EST

Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

Dec 07, 2020 7:30am EST

Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Nov 18, 2020 7:00am EST

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical